๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of bisantrene in malignant lymphomas

โœ Scribed by Thomas P. Miller; John D. Cowan; Barbara A. Neilan; Stephen E. Jones


Publisher
Springer
Year
1986
Tongue
English
Weight
291 KB
Volume
16
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Phase II evaluation of bisantrene hydroc
โœ David S. Alberts; Nancy Mason-Liddil; Stephanie J. Green; John D. Cowan; William ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› Springer US ๐ŸŒ English โš– 250 KB

Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m 2. The initial bisantrene dosing sche

Phase II trial of bisantrene in patients
โœ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s

Phase I/II study of bisantrene in childh
โœ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect